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Abstract
Aims This study aims to develop the first race-specific and sex-specific risk prediction models for heart failure with preserved
(HFpEF) and reduced ejection fraction (HFrEF).
Methods and results We created a cohort of 1.8 million individuals who had an outpatient clinic visit between 2002 and
2007 within the Veterans Affairs (VA) Healthcare System and obtained information on HFpEF, HFrEF, and several risk factors
from electronic health records (EHR). Variables were selected for the risk prediction models in a ‘derivation cohort’ that
consisted of individuals with baseline date in 2002, 2003, or 2004 using a forward stepwise selection based on a change in
C-index threshold. Discrimination and calibration were assessed in the remaining participants (internal ‘validation cohort’).
A total of 66 831 individuals developed HFpEF, and 92 233 developed HFrEF (52 679 and 71 463 in the derivation cohort) over
a median of 11.1 years of follow-up. The HFpEF risk prediction model included age, diabetes, BMI, COPD, previous MI, anti-
hypertensive treatment, SBP, smoking status, atrial fibrillation, and estimated glomerular filtration rate (eGFR), while the
HFrEF model additionally included previous CAD. For the HFpEF model, C-indices were 0.74 (SE = 0.002) for white men,
0.76 (0.005) for black men, 0.79 (0.015) for white women, and 0.77 (0.026) for black women, compared with 0.72 (0.002),
0.72 (0.004), 0.77 (0.017), and 0.75 (0.028), respectively, for the HFrEF model. These risk prediction models were generally
well calibrated in each race-specific and sex-specific stratum of the validation cohort.
Conclusions Our race-specific and sex-specific risk prediction models, which used easily obtainable clinical variables, can be a
useful tool to implement preventive strategies or subtype-specific prevention trials in the nine million users of the VA
healthcare system and the general population after external validation.
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Introduction
Heart failure (HF) is a common condition with an estimated
prevalence of 6.2 million in the USA.1 It carries a poor
prognosis, including a 5 year mortality of 50%,2 and adds
substantially to healthcare costs.3 The two major subtypes
of HF, heart failure with preserved (HFpEF) and reduced
ejection fraction (HFrEF), are increasingly regarded as distinct
conditions.4 In part, this distinction arises because patients
with overt HFpEF and HFrEF present with distinct ventricular
remodelling5 and have responded differently to pharmaco-
logical agents in randomized trials on hospitalizations and
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mortality outcomes.6,7 Although guidelines have called for a
greater focus on prevention of HF to curtail its growing
burden,8,9 the majority of prospective studies have not
been able to differentially examine the risk of developing
HFrEF or HFpEF. As a result, there is a lack of evidence on
subtype-specific risk factors, preventing the development of
risk prediction models for HFpEF and HFrEF. Previous
studies10,11 have developed such models, but these were
not stratified by race or sex, which could be clinically impor-
tant to predict disease. Hence, we used a large electronic
health record (EHR) database from the Veterans Health
Administration (VA) with more than 1.9 million individuals
to create a prospective cohort to study incident HFpEF and
HFrEF events. We compared associations between each HF
subtype for a wide range of risk factors and developed the




For this study, we utilized a previously described cohort12
comprising all patients with at least one primary care visit
at a VA facility who had at least one outpatient lipid result be-
tween 2002 and 2007 and a blood pressure measurement
within 30 days of this index lipid testing. These restrictions
reduce misclassification biases in that infrequent users of
the VA are more likely to have systematically inaccurate mea-
surements of baseline characteristics or outcomes.13 Baseline
entry into the cohort was the date of lipid testing. This cohort
was created using data from the VA corporate data
warehouse (CDW)14 linked to the Centers for Medicaid and
Medicare Services (CMS) and National Death Index (NDI)15
databases. We excluded individuals with a history of severe
co-morbidities at baseline including cancer, dialysis, and
major mental health disorder (Supporting Information,
Table S1), those of non-white or non-black race, those with
HF before or up to 30 days after baseline, or those who died
within 30 days of baseline date Those with baseline date in
2002, 2003, or 2004 were allocated to the ‘derivation cohort’
with the remaining individuals (baseline date in 2005 or
2006) serving as the internal ‘validation cohort’.
Exposure definitions
This extensive EHR resource contains International Classifica-
tion of Diseases (ICD) codes, lab results (sodium, potassium,
creatinine, and major lipids), anthropometric measurements
(blood pressure, height, and weight), medication information
(blood pressure medications and statins, see Supporting
Information, Table S2 for more detail) and demographic
variables (age, sex, ethnicity, and race) in a structured format.
Diabetes mellitus was defined as the use of a diabetes medi-
cation prior to the baseline date plus either two ICD-9-CM di-
agnosis codes 250.xx or the use of at least one 250.xx code in
combination with a VA primary care visit.16 Smoking history
was categorized as current, former, or never with an
algorithm developed and validated within the VA medical
records data.17 We used ICD-9 codes to define previous
MI (410–411.x), CAD (410–414.x), COPD (490–496.x, 510.x,
and 781.5x), and atrial fibrillation (427.31). Anaemia was de-
fined as a haemoglobin <13.5 g/dL for men, a haemoglobin
<12 g/dL for women, or an ICD-9 code of anaemia
(280–285.x). Estimated glomerular filtration rate (eGFR) was
estimated from creatinine using the CKD-EPI equation.18 For
sodium, potassium, and creatinine, we selected the closest
measurement in the EHR on or before baseline date up to a
year prior. Medication status was defined as having an active
prescription at the time of baseline, meaning their baseline
date fell between the date the prescription was picked up/
mailed and the end of their supply.
Outcome definition
Ejection fraction (EF) values were extracted from echocardio-
gram reports, radiology reports, and clinical notes (to ensure
capture of EF values measured outside the VA) using a vali-
dated natural language processing tool in a process described
elsewhere19 and used in previous studies.20,21 HF patients
were identified as those with an ICD-9 code of 428.x or
ICD-10 code of I50.x. We defined incident HFpEF as the first
instance of an HF code within 6 months of an echocardio-
gram EF ≥ 50% and incident HFrEF as the first instance of
an echocardiogram EF ≤ 40% in patients with an HF code. If
patients met criteria for both subtypes, the subtype that pre-
sented first was considered so that outcomes were mutually
exclusive. Those with HF but no EF value (unclassified HF;
N = 51 561; 23% of all HF cases) and those with EF between
40% and 50% (mid-range HF; N = 15 083, 7% of all HF cases)
were included in the at-risk population but censored at first
HF event. We chose not to consider mid-range HF as either
HFpEF or HFrEF because they are likely a mix of the two
aetiologies.22
Statistical analysis
In the derivation cohort, we used Cox regression adjusted for
age, sex, race, and ethnicity to estimate the hazard ratios
(HR) and 95% confidence intervals (95% CI) between risk
factors and each HF subtype, censoring at the other subtype
of HF, unclassified HF, mid-range HF, death, or end of
follow-up (31 December 2016), whichever came first. A
cause-specific Cox model was chosen over a competing risk
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model used in previous studies10,11 because results between
the approaches were similar, but cause-specific Cox models
were much less computationally intensive, especially for a
cohort of this size.
We selected the variables to be included in the HFrEF and
HFpEF models independently, using the entire derivation co-
hort (i.e. not stratified by race and sex). Continuous variables
that displayed non-linear associations were modelled using
fractional polynomials, initially in a model that included age,
sex, and race, then estimated again after the final model
was selected. To select variables, we started with an initial
reference model that included age, sex, and race and calcu-
lated the change in Harrell’s C-index23–25 of adding each risk
factor listed in Table 1 individually (except for individual anti-
hypertensive medications). In a forward stepwise manner, we
added the variable that most increased the C-index to the ref-
erence model until no variable had an improvement greater
than 0.002. Inspection of log–log plots indicated that the
proportional hazards assumption was met for all variables
in both final models. We took an available-case approach,
which restricted to those with complete data on the refer-
ence model and tested variable.
After variable selection, we used Cox regression to
estimate regression coefficients and baseline survival
(Supporting Information, Tables S3–S5) within each race-
stratum and sex-stratum of the derivation cohort, which
were used to calculate predicted 10 year risk for each indi-
vidual in the validation cohort. In each race-specific and
sex-specific stratum, we evaluated discrimination of the
models in the validation cohort using Harrell’s C-index
and evaluated calibration by plotting mean quantiles
(deciles for men, quintiles for women) of predicted 10 year
risk against observed 10 year risk derived from Kaplan–
Meier curves. We compared our models with an existing
one for HFpEF,10 the multi-cohort International Collabora-
tion on Heart Failure Subtypes (ICHFS) HFpEF model.
Table 1 Baseline characteristics in the derivation cohort
White men Black men White women Black women
N total 1 145 867 173 246 33 419 10 081
Age (SD)a, years 63.6 (9.7) 57.3 (10.3) 56.5 (11.4) 49.3 (7.4)
Hispanic or Latino ethnicity 53 253 (4.7) 3420 (2.0) 1064 (3.2) 109 (1.1)
SBP (SD)a, mmHg 137.5 (18.7) 139.4 (19.8) 132.9 (19.5) 133.1 (19.3)
DBP (SD), mmHg 77.2 (10.8) 80.6 (11.8) 75.1 (10.7) 78.0 (11.4)
BMI (SD), kg/m2 29.3 (5.3) 29.2 (5.7) 29.6 (6.7) 30.5 (6.2)
N missing 3213 292 98 6
HDL-c (SD)a, mg/dL 44.1 (12.9) 48.7 (15.4) 55.4 (16.1) 57.3 (16.8)
LDL-c (SD), mg/dL 117.1 (34.6) 121.0 (37.2) 126.3 (36.4) 123.5 (37.0)
N missing 55 463 6711 1244 340
Total cholesterol (SD), mg/dL 193.1 (40.8) 196.2 (42.1) 211.8 (41.8) 202.3 (41.1)
N missing 541 135 13 8
Ln-triglycerides (SD), mg/dL 5.0 (0.6) 4.8 (0.6) 4.9 (0.6) 4.6 (0.5)
N missing 50 308 6932 1565 417
eGFR (SD), mL/min/1.73 m2 75.2 (17.3) 85.4 (21.0) 79.0 (18.4) 93.1 (20.7)
N missing 168 397 22 397 5436 1401
Sodium (SD), mmol/L 139.5 (2.9) 139.6 (2.8) 139.4 (2.7) 139.3 (3.1)
N missing 195 678 22 986 5623 1410
Potassium (SD), mmol/L 4.4 (0.4) 4.2 (0.4) 4.2 (0.4) 4.0 (0.4)
N missing 190 636 22 611 5576 1402
Current smoker (%)a 185 842 (16.2) 41 973 (24.2) 6728 (20.1) 2101 (20.8)
Statin medication (%)a 386 851 (33.8) 34 214 (19.9) 6657 (19.9) 993 (9.9)
Antihypertensive medication (%)a 603 223 (52.6) 92 404 (53.3) 12 524 (37.5) 4078 (40.5)
ACE inhibitors (%)a 333 151 (29.1) 47 912 (27.7) 5196 (15.6) 1423 (14.1)
ARB (%)a 31 994 (2.8) 4126 (2.4) 731 (2.2) 188 (2.7)
Beta-blockers (%)a 248 749 (21.7) 26 634 (15.4) 4591 (13.7) 1166 (11.6)
Calcium channel blockers (%)a 180 163 (15.7) 38 432 (22.2) 3536 (10.6) 1431 (14.2)
Diuretics (%)a 209 979 (18.3) 44 609 (25.8) 5866 (17.6) 2399 (23.8)
Previous MI (%)a 71 787 (6.3) 6225 (3.6) 749 (2.2) 116 (1.2)
Previous CAD (%)a 297 358 (26.0) 21 250 (12.3) 2876 (8.6) 442 (4.4)
Diabetes (%)a 265 236 (23.2) 45 385 (26.2) 4098 (12.3) 1280 (12.7)
COPD (%)a 151 750 (13.2) 17 725 (10.2) 5453 (16.3) 1364 (13.5)
Anaemia (%)a 118 516 (10.3) 33 797 (19.5) 2863 (8.6) 2096 (20.8)
Atrial fibrillation (%)a 51 401 (4.5) 2074 (1.2) 584 (1.8) 35 (0.4)
aNo missing.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-c, high density lipo-
protein cholesterol; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LDL-c, low
density lipoprotein cholesterol; MI, myocardial infarction; SBP, systolic blood pressure.
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Analyses were carried out using Stata 15 (StataCorp LLC,
College Station, Texas).
Research ethics statement
This study was approved by the Institutional Review Boards at
VA Boston Healthcare System and Emory University. This
study was restricted to secondary data analysis, and thus,
the requirement for informed consent from study participants
was waived.
Results
Among Veterans 40–80 years of age at baseline, 66 831 de-
veloped HFpEF, and 92 233 developed HFrEF (52 679 and
71 463, respectively, in the derivation cohort). Table 1 shows
baseline characteristics within each race-specific and
sex-specific stratum of the derivation cohort (see Supporting
Information, Tables S6 for baseline characteristics of the
validation cohort).
Risk factors for heart failure with preserved
ejection fraction and heart failure with reduced
ejection fraction
Associations between risk factors and each HF subtype
adjusted for age, sex, race, and ethnicity are shown in
Table 2. Many associations were in similar direction for
HFpEF and HFrEF, but there were notable quantitative
differences for some important cardiometabolic risk factors.
Specifically, systolic blood pressure (SBP), body mass index
(BMI), antihypertensive medication use, and COPD
were stronger risk factors for HFpEF, while male sex, previ-
ous MI, and previous CAD were stronger risk factors for
HFrEF.
Risk prediction models for heart failure with
preserved ejection fraction and heart failure with
reduced ejection fraction
The HFpEF risk prediction model included age, diabetes, BMI,
COPD, previous MI, antihypertensive treatment, SBP,
Table 2 Risk factors for HFpEF and HFrEF in the derivation cohort
HFpEF HFrEF
HR (95% CI) HR (95% CI)
Age (per 10 years) 1.38 (1.37–1.40) 1.28 (1.27–1.29)
Female sex 0.89 (0.85–0.94) 0.44 (0.41–0.47)
Black race 1.37 (1.34–1.40) 1.36 (1.34–1.39)
Hispanic or Latino ethnicity 0.99 (0.95–1.04) 1.07 (1.03–1.07)
SBP (per 20 mmHg) 1.26 (1.25–1.27) 1.12 (1.11–1.13)
DBP (per 10 mmHg) 1.00 (1.00–1.01) 0.99 (0.98–1.00)
BMI (per 5 kg/m2) 1.48 (1.47–1.49) 1.20 (1.20–1.21)
HDL-c (per 15 mg/dL) 0.83 (0.82–0.84) 0.81 (0.80–0.81)
LDL-c (per 35 mg/dL) 0.88 0.87–0.88) 0.91 (0.90–0.92)
Total cholesterol (per 40 mg/dL) 0.92 (0.91–0.93) 0.95 (0.94–0.96)
Ln-triglycerides (per 0.5 Ln-mg/dL) 1.16 (1.15–1.17) 1.15 (1.14–1.16)
eGFR (per 15 mL/min/1.73 m2) 0.88 (0.87–0.88) 0.90 (0.89–0.90)
Sodium (per 3 mmol/L) 0.88 (0.88–0.89) 0.90 (0.89–0.90)
Potassium (per 0.5 mmol/L) 0.95 (0.94–0.96) 1.02 (1.01–1.02)
Current smoker (versus never) 1.52 (1.48–1.57) 1.80 (1.75–1.85)
Statin medication 1.20 (1.18–1.23) 1.31 (1.29–1.33)
Antihypertensive medication 2.28 (2.25–2.33) 1.98 (1.95–2.02)
ACE inhibitors 1.86 (1.82–1.89) 1.72 (1.69–1.74)
ARB 1.56 (1.50–1.63) 1.35 (1.30–1.40)
Beta-blockers 1.79 (1.76–1.83) 1.82 (1.79–1.85)
Calcium channel blockers 1.74 (1.71–1.78) 1.45 (1.43–1.48)
Diuretics 2.14 (2.11–2.19) 1.69 (1.66–1.72)
Previous MI 2.85 (2.78–2.93) 4.18 (4.10–4.26)
Previous CAD 1.73 (1.69–1.76) 2.69 (2.65–2.74)
Diabetes 2.31 (2.27–2.35) 2.07 (2.04–2.11)
COPD 2.14 (2.09–2.19) 1.58 (1.55–1.62)
Atrial fibrillation 2.24 (2.17–2.32) 2.21 (2.15–2.27)
Anaemia 1.61 (1.57–1.65) 1.45 (1.42–1.48)
Adjusted for age, sex, race, and ethnicity
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-c, high density lipo-
protein cholesterol; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LDL-c, low
density lipoprotein cholesterol; MI, myocardial infarction; SBP, systolic blood pressure.
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smoking status, atrial fibrillation, and eGFR, while the HFrEF
model additionally included previous CAD. Age, BMI, SBP,
and eGFR were modelled non-linearly for both HFpEF and
HFrEF, each using second degree polynomials. In both
models, we tested for inclusion of interactions terms for
each risk factor with age, but none increased C-index by
more than 0.002. The order in which variables were added
during variable selection and the corresponding C-index
for each model are shown in the Supporting Information,
Figure S1. Race-specific and sex-specific regression
coefficients for each model are shown in the Supporting
Information, Table S3.
In the validation cohort, the HFpEF model C-indices were
0.74 (SE = 0.002) for white men, 0.76 (0.005) for black men,
0.79 (0.015) for white women, and 0.77 (0.026) for black
women, and 0.72 (0.002), 0.72 (0.004), 0.77 (0.017), and
0.75 (0.028), respectively, for the HFrEF model (Table 3). In
this population, our model discriminated better than the
ICHFS HFpEF model, which had C-indices of 0.66 (0.003),
0.71 (0.006), 0.78 (0.015), and 0.73 (0.025) for white men,
black men, white women, and black women, respectively.
We could not assess the performance of the ICHFS HFrEF
model because it included left ventricular hypertrophy
(LVH) and left bundle branch block (LBBB), variables that
were not available in our dataset. Our risk prediction models
were generally well calibrated in each race-specific and
sex-specific stratum of the internal validation cohort
(Figure 1). We developed an online tool that calculates one’s
predicted 10 year risk of HFrEF and HFpEF (https://bos-mav.
github.io/HFRiskCalc/).
The ICHFS HFpEF model appeared to underpredict risk, par-
ticularly in black men and women (Figure 1A). For black men,
the ICHFS HFpEF model had a mean predicted 10 year risk of
5.2% in the top decile, while mean observed 10 year risk
was 9.3%. For black women the mean predicted 10 year
risk was 2.5% in the top quintile compared with a mean
observed 10 year risk of 3.8%.
Predicted 10 year risk for heart failure with
preserved ejection fraction versus heart failure
with reduced ejection fraction
Distributions of 10 year risk of HFpEF and HFrEF are shown in
Figure 2. While predicted 10 year risk estimates were strongly
correlated between the HF subtypes (Pearson’s r = 0.86 in the
whole validation cohort), there were differences in absolute
risk. Forty-five per cent of white men and 52% of black men
with predicted 10 year risk of HFrEF over 5% had HFpEF risk
below 5%. For white and black women, 66% and 77%, respec-
tively, of those with HFpEF risk above 5% had HFrEF risk
below 5% (Supporting Information, Table S7).
Discussion
Using an EHR-based cohort of over 1.9 million individuals, we
quantified the associations of several risk factors with
incident HFpEF and HFrEF events, identifying quantitative
differences in the magnitude of estimates. Furthermore, we
developed the first race-specific and sex-specific risk predic-
tion models for HFpEF and HFrEF, using a number of clinical
risk factors routinely recorded in the EHR that will enable
easy applicability.
Previous prospective studies examining risk factors for inci-
dent HF subtypes10,11,26–30 have been moderately powered
and mostly confined to the four prospective studies that
make up the International Collaboration on Heart Failure
Subtypes (ICHFS).10 In analysis of >100 000 incident HF
events, we found results that were generally concordant with
those previous purpose-designed cohorts in relation to direc-
tion and magnitude for traditional cardiovascular risk factors
with HF subtypes (Supporting Information, Table S8),
although our study was able to document these associations
with greater precision. The similarity of findings between our
Table 3 C-indices (SE) for HFpEF and HFrEF risk prediction models
Derivation cohort Validation cohort
N total Events C-index (SE) N total Events C-index (SE)
HFpEF
White men 974 622 37 349 0.730 (0.001) 393 269 10 541 0.739 (0.002)
Black men 150 578 6978 0.753 (0.003) 73 978 1968 0.764 (0.005)
White women 27 899 963 0.790 (0.007) 13 911 242 0.793 (0.015)
Black women 8674 254 0.775 (0.014) 6074 81 0.772 (0.026)
HFrEF
White men 974 622 51 153 0.715 (0.001) 393 269 15 327 0.724 (0.002)
Black men 150 578 9772 0.706 (0.003) 73 978 3235 0.719 (0.004)
White women 27 899 635 0.761 (0.009) 13 911 212 0.769 (0.017)
Black women 8674 202 0.728 (0.019) 6074 80 0.745 (0.028)
In HFpEF validation cohort, model includes age, diabetes, BMI, COPD, previous MI, antihypertensive treatment, SBP, smoking status, atrial
fibrillation, and eGFR. In HFrEF validation cohort, model includes age, diabetes, BMI, COPD, previous MI, previous CAD, antihypertensive
treatment, SBP, smoking status, atrial fibrillation and eGFR
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Figure 1 (A) Calibration plots in the validation cohort for HFpEF for (a) white men, (b) black men, (c) white women, and (d) black women. Mean pre-
dicted 10 year risk of HFpEF within each quantile (deciles for men and quintiles for women) against observed 10 year risk derived from Kaplan–Meier
curves. Blue diamonds represent the current analysis, red triangles represent results using the International Collaboration on Heart Failure Subtypes
model variables, weights (beta-coefficients), and baseline survival. (B) Calibration in the validation cohort for HFrEF for (a) white men, (b) black men,
(c) white women, and (d) black women. Mean predicted 10 year risk of HFrEF within each quantile (deciles for men and quintiles for women) against
observed 10 year risk derived from Kaplan–Meier curves.
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EHR-based cohort and purpose-designed cohorts may indi-
cate that the risk factors for HF subtypes are reliably captured
by EHRs and potentially generalizable across populations.
For many risk factors, the present study is the first or larg-
est prospective study to assess relationships with incident
HFrEF and HFpEF. While triglycerides levels were positively
associated with both HFpEF and HFrEF, LDL-c levels were in-
versely associated with both outcomes. The meaning of this
LDL-c association, which was also reported for total incident
HF by a Danish cohort of 113 554 individuals,31 is not clear,
but it could be due to confounding by statin usage. A previ-
ous study has reported that lower serum sodium at time of
diagnosis can predict mortality and hospitalization in those
with existing HFpEF,21 and our study observed an inverse
association between sodium and incident events as well.
Our study has also noted associations of less well studied risk
factors with incident HFpEF and HFrEF, including COPD, anae-
mia, eGFR, and specific blood pressure medications.
A key advantage of the present study’s statistical power
was the ability to detect quantitative differences in risk factor
profiles between HFrEF and HFpEF. While there were similar-
ities in the direction of associations, there are notable differ-
ences in the magnitude of associations for a number of
important cardiometabolic risk factors, like sex, SBP, antihy-
pertensive medications, BMI, previous CAD/MI, and COPD.
Our results add to the existing evidence that HFrEF and
HFpEF may result from distinct pathophysiologic processes.4
It is likely that CAD through myocardial injury or hibernation
is a causal precedent for HFrEF. In contrast, some have
hypothesized a mechanism for HFpEF in which obesity,
diabetes, and COPD induce a proinflammatory reaction in
the myocardium, which may lead to HFpEF.32
While multiple risk prediction models exist for total
HF,33–35 only two previous papers have developed models
for HF subtypes. One11 relied exclusively on CMS data and
had a high proportion (62%) of unspecified HF and the other10
combined data from the ICHFS cohorts. Our HFpEF model
contained all of the ICHFS HFpEF model variables, as well as
diabetes, COPD, smoking status, atrial fibrillation, and eGFR.
The additional variables and regression coefficients more tai-
lored to our population lead to better discrimination than
the ICHFS HFpEF model in each race-specific and sex-specific
stratum. The ICHFS HFrEF model and our HFrEF model were
similar in that both contained age, SBP, BMI, antihypertensive
treatment, diabetes, smoking status, and previous MI. How-
ever, the ICHFS HFrEF model additionally included LVH and
LBBB, which were not available in our dataset, and our HFrEF
model additionally included COPD, previous CAD, atrial fibril-
lation, and eGFR, none of which were assessed in their analy-
sis. Our study was designed to use clinical variables that are
available in any healthcare system and are not indicative of
already present heart disease (such as LBBB and LVH).
Therefore, we did not include biomarkers such as high
sensitivity troponin and natriuretic peptides that have been
previously evaluated in purpose-designed prospective cohort
studies and shown to improve discrimination.29
Stratifying by race and sex appears to be important for ac-
curate prediction of HFpEF and HFrEF. Because the ICHFS
Figure 2 Distributions of predicted 10 year risk of HFpEF and HFrEF in the validation cohort. Ten year risk of HFpEF and HFrEF was estimated using
race-specific and sex-specific weights and baseline survival. Blue and white bars represent HFpEF and HFrEF, respectively. Values of predicted 10 year
risk were truncated at 15%.
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models were derived from cohorts comprising almost 95%
white European ancestry, this earlier work could not evaluate
the impact of stratification by race and sex. Consequently,
the ICHFS HFpEF model underpredicted risk in black men
and women, which in the clinical setting, may lead to
undertreatment and poorer outcomes. Because the burden
of HF is generally greater in black individuals than white indi-
viduals in both our cohort and previous studies,36,37 it is im-
portant to have accurate prediction of HF to inform clinical
decisions in these understudied populations.
We found that over 45% of men with high predicted
10 year risk (above 5%) of developing HFrEF had low pre-
dicted 10 year risk (below 5%) of HFpEF, and over 65% of
women with high predicted 10 year risk of HFpEF had low
predicted 10 year risk of HFrEF, underscoring the need for
subtype-specific risk prediction models. This is not surprising
given that, although the HFpEF and HFrEF models contained
almost the same variables, the relative importance (i.e. the
order in which the variables were added to models) and
weighting for some differed considerably. ACE inhibitors
(ACEI),38 angiotensin-receptor blockers (ARB),39 angiotensin
receptor neprilysin inhibitors (ARNI),40,41 beta-blockers,42
mineralocorticoid receptor antagonists (MRA),43,44 and SGLT2
inhibitors45 reduce morbidity and mortality in those with
overt HFrEF, but no treatments have been definitely proven
to benefit HFpEF. Hence, prevention of HFpEF is crucial to
lessen its burden. Previous trials have shown that HF preven-
tion is possible,46–49 but given the differential effects of
therapies in overt HFpEF and HFrEF, it is likely that primary
prevention requires subtype-specific approaches as well.
Our risk models would allow for efficient screening using
the EHR to identify high-risk individuals who may be good
candidates for primary prevention trials of each subtype at
relatively low cost because they use variables already
routinely measured in clinical practice.
Strengths and limitations
There are a number of strengths of this study. It is the largest
investigation of incident events of HF subtypes, and by using
the rich EHR data in the VA, we were able to examine a wide
range of potential HF risk factors. We were able to determine
who had active prescriptions at baseline, including informa-
tion on specific antihypertensive medications. By analysing
the EHR data, we did not rely on any self-reported defini-
tions, which can inadequately characterize predictors,50,51
and HF diagnosis.52 Because our baseline dates ranged from
2002 to 2007, we have a more modern cohort than previous
studies, more relevant to the current clinical setting. Lastly,
based on our established expertise in curating and subtyping
HF in the VA databases,53 we were able to accurately capture
incident cases of HFpEF and HFrEF, including those that hap-
pened outside the VA though linkage with CMS databases.
The major limitation of our study is that we could not ex-
ternally validate our risk prediction models in fully indepen-
dent populations, primarily because no other large-scale
dataset includes phenotyped HF subtypes and all the vari-
ables in our risk prediction models. The relative proportion
of women and minorities was low, but this resource included
a larger number of black men, white women, and black
women than any previous study looking at incident HFrEF
and HFpEF. Excluding individuals with missing variables in
the models could introduce selection bias, but those individ-
uals made up a small proportion of the dataset (13%) and had
similar traditional cardiovascular risk factors to those in-
cluded in the risk prediction analysis (Supporting Information,
Table S9).
Conclusions
Using a large EHR database, we identified quantitatively
different associations of several cardiometabolic exposures
with HFpEF and HFrEF. For HF subtypes, this EHR-based
cohort behaved similarly to traditional prospective cohorts,
possibly indicating that its generalizability could extend to
healthcare systems outside the VA. We developed the first
race-specific and sex-specific models for HFrpEF and HFrEF,
which performed well in our diverse population and used var-
iables easily obtainable in clinical practice. A large proportion
of men with high risk of HFrEF had low risk of HFpEF and vice
versa for women, indicating a need for subtype specific
models. These risk prediction models could help to identify
individuals at high-risk of future HF events for clinical inter-
vention or prevention trials in the nine million regular users
of the VA or in the general population once externally vali-
dated in independent datasets. An online tool was developed
to allow for implementation of this risk calculator in the
clinical setting.
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